Moneycontrol
    Moneycontrol PRO
    LAMF
    LAMF

    Active Pharmaceutical Ingredients

    Jump to

    • Rakesh Jhunjhunwala-backed Concord Biotech files draft papers to float IPO

    • Local manufacturing of 35 APIs started after PLI scheme: Mansukh Mandaviya

    • USFDA pulls up Aurobindo Pharma for manufacturing lapses at API plant

    • PE major CVC Capital Partners in talks to pick up minority stake in Shilpa Medicare’s API business

    • API imports stood at Rs 28,529 crore, exports at Rs 32,856 crore in FY21: Mansukh Mandaviya

    • Indian pharma firms go local seeking to end reliance on China

    • Need to boost local API production for India to become self-reliant in coming years: Unichem Laboratories

    • Budget 2017: Weighted deductions for incurring pharma R&D should continue

    • Hikal's Bengaluru unit undergoes 'successful' USFDA inspection

    • Continue to be positive on housing finance companies: SP Tulsian

    • Laurus Labs IPO opens: Analysts bullish but say valuations high

    • API imports from China move up to 65% in 2015-16

    • Sharon Bio up 20% on USFDA approval for API plant in Maharashtra

    • Expect growth to continue going forward: Lincoln Pharma

    • Cipla in pact with Russian firm for HIV, Hepatitis C drugs

    • USFDA observations on 2 units not to impact products: Natco

    • Alkem's Mandva plant gets establishment nod from USFDA

    • US API import ban applies only to one drug: Biocon CMD

    • Mankind Pharma to invest Rs 200 cr by mid-2016

    • Strides Shasun suspends production at Cuddalore unit block

    • Granules India gets USFDA nod for generic Ibuprofen tablets

    • Cadila to delist from Ahmedabad Stock Exchange

    • Two new plants to aid topline growth: Nutraplus

    • Kopran jumps 15% on shares allotment to promoter group co

    • Ranbaxy plunges 20% on USFDA ban on Toansa API plant

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347